NCT05586620

Brief Summary

Punctal stenosis is a progressive constriction of the puncta with resultant epiphora. One of the most effective treatment options is 1- to 4-snip punctoplasty combined with or without Mitomycin-C.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2021

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2022

Completed
9 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 10, 2022

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 15, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 19, 2022

Completed
Last Updated

October 19, 2022

Status Verified

October 1, 2022

Enrollment Period

1 year

First QC Date

October 15, 2022

Last Update Submit

October 15, 2022

Conditions

Outcome Measures

Primary Outcomes (8)

  • Punctal patency

    Punctum will be assessed by inspection of the lid by slitlamb examination, whither obstructed or not

    Baseline

  • Punctal patency

    Punctum will be assessed by inspection of the lid by slitlamb examination, whither obstructed or not

    1 week postoperative

  • Punctal patency

    Punctum will be assessed by inspection of the lid by slitlamb examination, whither obstructed or not

    1 month postoperative

  • Punctal patency

    Punctum will be assessed by inspection of the lid by slitlamb examination, whither obstructed or not

    3 months postoperative

  • Presence of Epiphora

    It will be assessed by inspection of the lid by slitlamb examination.

    Baseline

  • Presence of Epiphora

    It will be assessed by inspection of the lid by slitlamb examination.

    1 week postoperative

  • Presence of Epiphora

    It will be assessed by inspection of the lid by slitlamb examination.

    1 month postoperative

  • Presence of Epiphora

    It will be assessed by inspection of the lid by slitlamb examination.

    3 month postoperative

Study Arms (2)

3-snip punctoplasty

ACTIVE COMPARATOR
Procedure: 3-snip punctoplasty

3-snip punctoplasty with mitomycin C

ACTIVE COMPARATOR
Procedure: 3-snip punctoplasty and Mitomycin C

Interventions

punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease.

3-snip punctoplasty

punctoplasty, more commonly known as watery eye surgery, is an ophthalmic surgical procedure performed to correct punctal stenosis (a condition that causes tears to overflow from the eyes) by widening the punctal opening to allow the tears to drain with ease. Mitomycin C is a chemotherapeutic agent that acts by inhibiting DNA synthesis

3-snip punctoplasty with mitomycin C

Eligibility Criteria

Age16 Years - 63 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients with recurrence of punctal stenosis at the end of 1 month following punctal dilatation.

You may not qualify if:

  • patients with associated lacrimal passage obstruction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ehab tharwat

Damietta, New Damietta, 34517, Egypt

Location

MeSH Terms

Interventions

Mitomycin

Intervention Hierarchy (Ancestors)

MitomycinsIndolequinonesQuinonesOrganic ChemicalsAzirinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

October 15, 2022

First Posted

October 19, 2022

Study Start

June 1, 2021

Primary Completion

June 1, 2022

Study Completion

June 10, 2022

Last Updated

October 19, 2022

Record last verified: 2022-10

Locations